Ohm Oncology is a drug development company committed to treating drug-resistant neoplasms and cancers with multi-mechanism compounds. It specializes in kinase targeting and developing pharmacophores capable of engaging multiple targets. The company provides OHM-581, a dual-inhibitor based on poly-pharmacophores that inhibit both BET and JAK kinases.